Device Trial Radar · NCT04279522
The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Aug 31, 2021
Primary completion
Jun 7, 2024
Study completion Jun 7, 2024
Sponsor
- Lead sponsor
- Neurolief Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 21, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The MOOD study will evaluate the safety and efficacy of a noninvasive, self-administered external Combined Occipital and Trigeminal Neurostimulation (eCOT-NS) treatment for Major Depressive Disorder (Relivion®DP). This is a prospective, multi-center, 2-arm randomized, double-blind, parallel-group, sham-controlled study. The study will include the following stages: 1. Screening, Eligibility evaluation and Randomization to Relivion®DP vs. Sham control (1:1 randomization) (Baseline - Day 0). 2. Daily treatment period: Active/Sham (Group A/B) treatment protocol (Baseline to end of 8 weeks). 3. Open label phase: Active treatment period of additional 8 weeks. After completion of the open label period the subject's participation in the study will be over.
Conditions
- MDD
Interventions
Relivion®DP- ActiveDevice
Relivion®DP- Active stimulation device
Relivion®DP- ShamDevice
Relivion®DP- Sham stimulation device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Depressive Symptoms, Measured by HDRS17 Total ScoreTime frame: 8 weeks from treatment initiation
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Kadima Neuropsychiatry Institute
La Jolla, California
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.